These Threats Facing Canopy Growth Stock Could Justify Selling it

Let’s dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip or leave well enough alone.

| More on:
A cannabis plant grows.

Source: Getty Images

Key Points

  • The Canadian cannabis sector faces significant challenges, with deteriorating fundamentals and growth stagnation, especially as the U.S. market remains largely inaccessible to foreign companies.
  • Canopy Growth and other Canadian cannabis producers struggle with declining revenues and heightened competition, prompting concerns among investors about the future viability and return potential.

The Canadian cannabis sector continues to remain relatively beaten down, despite some solid news coming out of the Trump administration that marijuana may be re-classified as a less-dangerous drug south of the border.

What was once a catalyst for Canadian cannabis stocks, many of which had their eye on the prize (which is the massive and growing market for cannabis consumption in the U.S.), the U.S. market may seem more closed than ever to foreign companies. Under President Trump, this seems to be even more true today than when his second term began.

This is certainly one of the key threats keeping investors in Canopy Growth (TSX:WEED) and other cannabis producers up at night.

Let’s dive into another couple of threats that investors in Canopy and the cannabis sector as a whole need to keep in mind.

Growth will need to resume

One of the key factors I think drives the price action in the chart above is the sheer fact that the underlying fundamentals of this sector have deteriorated considerably in recent years.

As I pointed out five or six years ago, when the cannabis boom was in full throttle, the accounting methodology, which allowed companies like Canopy to book plants grown as revenue (before they were sold to retailers or end consumers) led to a surge in perceived pro forma profitability in Canopy’s earlier years, but has also led to some stark negative downstream effects.

This past year, Canopy has seen revenue decline by nearly double-digit percentages in most time frames. That’s not good for any company. And in an industry that’s often thought of as a growth sector, a lack of top-line growth is something most investors simply can’t ignore.

Cannabis market continues to face challenges

Outside of certain markets like the U.S. that are seeing continued growth (as more states legalize pot), more mature markets like Canada that have allowed for cannabis sales for roughly seven years are seeing growth flatline. Market saturation, threats from the black market, and heightened competition for an already saturated market have led to deteriorating fundamentals for nearly all players in the Canadian market.

With the U.S. market seemingly off the table, at least for the next three years, investors in companies like Canopy need another catalyst to rely on for a bullish outlook.

In the absence of such a catalyst, this does appear to me to be a stock that’s worth selling right now.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

1 Cannabis Stock That’s My Speculative Sector Play

The cannabis boom has come and gone, but this cannabis stock may still have a chance to rise higher.

Read more »